CAPP2 in the Lancet

The CAPP2 long term follow up paper is now published

The Lancet. DOI: 10.1016/S0140-6736(20)30366-4

The take home message is that the cancer chemopreventive effect is even clearer than in the 2011 CAPP2 publication.

The protective effect of aspirin (600mg, 2 large tablets) against colorectal cancer has persisted in this long-term follow up of the CAPP2 trial, for up to 20 years.

Thank you to all the CAPP2 study participants and to the study participants in the ongoing CaPP3 trial, which is looking to see whether smaller doses of aspirin can be used to reduce the risk of cancer in Lynch syndrome.

Further information about the CAPP2 Lancet paper is in the CaPPtain's blog